LX-2761 is primarily used in the field of medical research, particularly in the study of metabolic disorders. It functions as a sodium-glucose cotransporter 2 (SGLT2) inhibitor, which makes it valuable in exploring treatments for conditions like diabetes. By inhibiting SGLT2, it helps reduce glucose reabsorption in the kidneys, leading to increased glucose excretion in urine and lower blood sugar levels. This mechanism is being investigated for its potential to improve glycemic control in patients with type 2 diabetes. Additionally, LX-2761 is studied for its possible benefits in managing heart failure and chronic kidney disease, as SGLT2 inhibitors have shown promise in reducing cardiovascular risks and preserving renal function. Its application extends to preclinical studies aimed at understanding its efficacy and safety profile for future therapeutic use.